Molecular mechanisms of action of antisense drugs

Biochimica et Biophysica Acta - Gene Structure and Expression

Volumn 1489, Issue 1, 1999, Pages 31-43

  Crooke, Stanley T ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

Antisense; Mechanism of action; RNase H

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CGP 69846A; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; RIBONUCLEASE H;

COVALENT BOND; DRUG MECHANISM; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVIEW; RNA CLEAVAGE; RNA METABOLISM;

ALTERNATIVE SPLICING; ANIMALS; DRUG DESIGN; HUMANS; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN BIOSYNTHESIS; RIBONUCLEASE H, CALF THYMUS; RNA; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA, CATALYTIC; SUBSTRATE SPECIFICITY;

EID: 0032700656     PISSN: 01674781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4781(99)00148-7     Document Type: Review

References (116)

1. Yacyshyn B.R., et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology. 114:(6):1998;1133-1142.
2. P.J. O'Dwyer, et al. Phase I/phamracokinetic/pharmacodynamic trial of raf-1 antisense ODN (ISIS 5132, CGP 69846A), in: 34th Annual Meeting of the American Society of Clinical Oncology, Los Angeles, CA, 1998.
3. S.T. Crooke (Ed.), Antisense Research and Application. Handbook of Experimental Pharmacology, Springer, Berlin, 1998.
4. Mizumoto K., Kaziro Y. Messenger RNA capping enzymes from eukaryotic cells. Progr. Nucleic Acid Res. Mol. Biol. 34:1987;1-28.
5. Ross J. Messenger RNA turnover in eukaryotic cells. Mol. Biol. Med. 5:1988;1-14.
6. Friedman D.I., Imperiale M.J. RNA 3′ end formation in the control of gene expression. Annu. Rev. Genet. 21:1987;453-488.
7. Manley J.L. Polyadenylation of mRNA precursors. Biochim. Biophys. Acta. 950:1988;1-12.
8. Padgett R.A., et al. Splicing of messenger RNA precursors. Annu. Rev. Biochem. 55:1986;1119-1150.
9. Green M.R. Pre-mRNA splicing. Annu. Rev. Genet. 20:1986;671-708.
10. Breslauer K.J., et al. Predicting DNA duplex stability from base sequence. Proc. Natl. Acad. Sci. USA. 83:1986;3746-3750.
11. Freier S.M., et al. Improved free-energy parameters for predictions of RNA duplex stability. Proc. Natl. Acad. Sci. USA. 83:(24):1986;9373-9377.
12. M. Chastain, Tinoco I., RNA structure as related to antisense drugs, in: Antisense Research and Applications, CRC Press, Boca Raton, FL, 1993, p. 55.
13. D.J. Ecker, in: Strategies for invasion of RNA secondary structure, in: S.T. Crooke, R. Lebleu (Eds.), Antisense Research and Applications, CRC Press, Boca Raton, FL, 1993, pp. 387-400.
14. Tuerk C., Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 249:1990;505-510.
15. Wyatt J.R., et al. Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc. Natl. Acad. Sci. USA. 91:(4):1994;1356-1360.
16. Wang K.Y., et al. A DNA aptamer which binds to and inhibits thrombin exhibits a new structural motif for DNA. Biochemistry. 32:1993;1899-1904.
17. Leroy J.-L., et al. Acid multimers of oligodeoxycytidine strands: stoichiometry, base-pair characterization, and proton exchange properties. Biochemistry. 32:1993;6019-6031.
18. Gehring K., Leroy J.L., Gueron M. A tetrameric DNA structure with protonated cytosine.cytosine base pairs (see comments). Nature. 363:(6429):1993;561-565.
19. S.T. Crooke (Ed.), Antisense Research and Application. Handbook of Experimental Pharmacology, Vol. 131, Springer, Berlin, 1998, p. 630.
20. C.F. Bennett, T.P. Condon, Use of antisense oligonucleotides to modify inflammatory processes, in: S.T. Crooke (Ed.), Antisense Research and Applications, Springer, Berlin, 1998, pp. 371-393.
21. Freier S.M., et al. Thermodynamics of antisense oligonucleotide hybridization. Mol. Cell. Biol. (Gene Regul.). 1:1992;95-107.
22. S.L. Thein, R.B. Wallace, The use of synthetic oligonucleotides as specific hybridization probes in the diagnosis of genetic disorders, in: K.E. Davies (Ed.), Human Genetic Diseases: A Practical Approach, IRL Press, Oxford, 1986, pp. 33-50.
23. C. Helene, J.-J. Toulme, Control of gene expression by oligonucleotides covalently linked to intercalating agents and nucleic acid-cleaving reagents, in: J.S. Cohen (Ed.), Oligonucleotides: Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL, 1989, pp. 137-172.
24. Helene C., Toulme J.-J. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim. Biophys. Acta. 1049:1990;99-125.
25. Monia B.P., et al. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J. Biol. Chem. 267:(28):1992;19954-19962.
26. Crooke R.M. In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Anti-Cancer Drug Design. 6:(6):1991;609-646.
27. Crooke, S.T., Oligonucleotide therapeutics, in: M.E. Wolff (Ed.), Burger's Medicinal Chemistry and Drug Discovery, Vol. 1, Wiley and Sons, New York, 1995, pp. 863-900.
28. Crooke S.T. Progress in antisense therapeutics. Hematol. Pathol. 9:(2):1995;59-72.
29. McManaway M.E., et al. Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide. Lancet. 335:1990;808-811.
30. Kulka M., et al. Site specificity of the inhibitory effects of oligo(nucleoside methylphosphonate)s complementary to the acceptor splice junction of herpes simplex virus type 1 immediate early mRNA 4. Proc. Natl. Acad. Sci. USA. 86:1989;6868-6872.
31. Zamecnik P.C., et al. Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc. Natl. Acad. Sci. USA. 83:1986;4143-4146.
32. Smith C.C., et al. Antiviral effect of an oligo(nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5. Proc. Natl. Acad. Sci. USA. 83:1986;2787-2791.
33. Dominski Z., Kole R. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA. 90:1993;8673-8677.
34. Agrawal S., et al. Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus (published erratum appears in Proc. Natl. Acad. Sci. USA, 86(5) (1989) 1504). Proc. Natl. Acad. Sci. USA. 85:(19):1988;7079-7083.
35. Lemaitre M., Bayard B., Lebleu B. Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site. Proc. Natl. Acad. Sci. USA. 84:(3):1987;648-652.
36. Rosolen A., et al. Antisense inhibition of single copy N-myc expression results in decreased cell growth without reduction of c-myc protein in a neuroepithelioma cell line. Cancer Res. 50:(19):1990;6316-6322.
37. Vasanthakumar G., Ahmed N.K. Modulation of drug resistance in a daunorubicin resistant subline with oligonucleoside methylphosphonates (published erratum appears in Cancer Commun. 2(8) (1990) 295). Cancer Commun. 1:(4):1989;225-232.
38. Sburlati A.R., Manrow R.E., Berger S.L. Prothymosin alpha antisense oligomers inhibit myeloma cell division. Proc. Natl. Acad. Sci. USA. 88:1991;253-257.
39. Zheng H., et al. Specific inhibition of cell-surface T-cell receptor expression by antisense oligodeoxynucleotides and its effect on the production of an antigen-specific regulatory T-cell factor. Proc. Natl. Acad. Sci. USA. 86:(10):1989;3758-3762.
40. Maier J.A.M., et al. Extension of the life-span of human endothelial cells by an interleukin-1α antisense oligomer. Science. 249:1990;1570-1574.
41. Crooke S.T. Molecular mechanisms of antisense drugs: RNase H. Antisense Nucleic Acid Drug Dev. 8:(2):1998;133-134.
42. Vickers T., et al. Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR element. Nucleic Acids Res. 19:(12):1991;3359-3368.
43. Ecker D.J., et al. Pseudo-half-knot formation with RNA. Science. 257:(5072):1992;958-961.
44. Saxena S.K., Ackerman E.J. Microinjected oligonucleotides complementary to the α-sarcin loop of 28 S RNA abolish protein synthesis in Xenopus oocytes. J. Biol. Chem. 265:1990;3263-3269.
45. Walker K., Elela S.A., Nazar R.N. Inhibition of protein synthesis by anti-5.8 S rRNA oligodeoxyribonucleotides. J. Biol. Chem. 265:1990;2428-2430.
46. Westermann P., Gross B., Hoinkis G. Inhibition of expression of SV40 virus large T-antigen by antisense oligodeoxyribonucleotides. Biomed. Biochim. Acta. 48:(1):1989;85-93.
47. Baker B.F. Decapitation of a 5′-capped oligoribonucleotide by o-phenanthroline:copper(II). J. Am. Chem. Soc. 115:(8):1993;3378-3379.
48. Baker B.F., Miraglia L., Hagedorn C.H. Modulation of eukaryotic initiation factor-4E binding to 5′-capped oligoribonucleotides by modified anti-sense oligonucleotides. J. Biol. Chem. 267:(16):1992;11495-11499.
49. Chiang M.Y., et al. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J. Biol. Chem. 266:(27):1991;18162-18171.
50. R.J. Crouch, M.-L. Dirksen, Ribonucleases H, in: S.M. Linn, R.J. Roberts (Eds.), Nucleases, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1985, pp. 211-241.
51. Crum C., et al. Complementary oligodeoxynucleotide mediated inhibition of tobacco mosaic virus RNA translation in vitro. Nucleic Acids Res. 16:(10):1988;4569-4581.
52. Haeuptle M.T., Frank R., Dobberstein B. Translation arrest by oligodeoxynucleotides complementary to mRNA coding sequences yields polypeptides of predetermined length. Nucleic Acids Res. 14:(3):1986;1427-1448.
53. Donis-Keller H. Site specific enzymatic cleavage of RNA. Nucleic Acids Res. 7:1979;179-192.
54. Kawasaki A.M., et al. Uniformly modified 2′-deoxy-2′-fluoro-phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets. J. Med. Chem. 36:(7):1993;831-841.
55. Sproat B.S., et al. Highly efficient chemical synthesis of 2′-O-methyloligoribonucleotides and tetrabiotinylated derivatives; novel probes that are resistant to degradation by RNA or DNA specific nucleases. Nucleic Acids Res. 17:1989;3373-3386.
56. Morvan F., Rayner B., Imbach J.L. Alpha-oligonucleotides: a unique class of modified chimeric nucleic acids. Anticancer Drug Des. 6:(6):1991;521-529.
57. Gagnor C., et al. Alpha-DNA.IX: Parallel annealing of alpha-anomeric oligodeoxyribonucleotides to natural mRNA is required for interference in RNase H mediated hydrolysis and reverse transcription. Nucleic Acids Res. 17:(13):1989;5107-5114.
58. Maher L.J. III, Wold B., Dervan P.B. Inhibition of DNA binding proteins by oligonucleotide-directed triple helix formation. Science. 245:1989;725-730.
59. P.S. Miller, Non-ionic antisense oligonucleotides, in: J.S. Cohen (Ed.), Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL, 1989, p. 79.
60. Mirabelli C.K., et al. In vitro and in vivo pharmacologic activities of antisense oligonucleotides. Anti-Cancer Drug Des. 6:(6):1991;647-661.
61. C.A. Stein, J.S. Cohen, Phosphorothioate oligodeoxynucleotide analogs, in: J.S. Cohen (Ed.), Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL, 1989, pp. 97-117.
62. Cazenave C., et al. Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides. Nucleic Acids Res. 17:1989;4255-4273.
63. Quartin R.S., Brakel C.L., Wetmur J.G. Number and distribution of methylphosphonate linkages in oligodeoxynucleotides affect exo- and endonuclease sensitivity and ability to form RNase H substrates. Nucleic Acids Res. 17:1989;7253-7262.
64. Furdon P.J., Dominski Z., Kole R. RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds. Nucleic Acids Res. 17:1989;9193-9204.
65. Eder P.S., Walder J.A. Ribonuclease H from K562 human erythroleukemia cells. J. Biol. Chem. 266:1991;6472-6479.
66. Monia B.P., et al. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268:(19):1993;14514-14522.
67. Giles R.V., Tidd D.M. Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures. Nucleic Acids Res. 20:1992;763-770.
68. Walder R.Y., Walder J.A. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA. 85:1988;5011-5015.
69. Minshull J., Hunt T. The use of single-stranded DNA and RNase H to promote quantitative 'hybrid arrest of translation' of mRNA/DNA hybrids in reticulocyte lysate cell-free translations. Nucleic Acids Res. 14:1986;6433-6451.
70. Gagnor C., et al. alpha-DNA VI: comparative study of alpha- and beta-anomeric oligodeoxyribonucleotides in hybridization to mRNA and in cell free translation inhibition. Nucleic Acids Res. 15:(24):1987;10419-10436.
71. Wu H., Lima W.F., Crooke S.T. Molecular cloning and expression of cDNA for human RNase H. Antisense Nucleic Acid Drug Dev. 8:(1):1998;53-61.
72. Knorre D.G., Vlassov V.V., Zarytova V.F. Reactive oligonucleotide derivatives and sequence-specific modification of nucleic acids. Biochimie. 67:(7-8):1985;785-789.
73. D. Knorre, V. Vlassov, V. Zarytova, Oligonucleotides linked to reactive groups, in: J. Cohen (Ed.), Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL, 1989, p. 179.
74. Vlassov V.V., et al. Sequence-specific chemical modification of double-stranded DNA with alkylating oligodeoxyribonucleotide derivatives. Gene. 72:1988;313-322.
75. Summerton J., Bartlett P.A. Sequence-specific crosslinking agents for nucleic acids. Use of 6-bromo-5,5-dimethoxyhexanohydrazide for crosslinking cytidine to guanosine and crosslinking RNA to complementary sequences of DNA. J. Mol. Biol. 122:(2):1978;145-162.
76. Webb T.R., Matteucci M.D. Hybridization triggered cross-linking of deoxyoligonucleotides. Nucleic Acids Res. 14:(19):1986;7661-7674.
77. Cooney M., et al. Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro. Science. 241:1988;456-460.
78. Le Doan T. Sequence-specific recognition, photocrosslinking and cleavage of the DNA double helix by an oligo-(alpha)-thymidylate covalently linked to an azidoproflavine derivative. Nucleic Acids Res. 15:1987;7749-7760.
79. Fedorova O.S., et al. Complementary addressed modification of double-stranded DNA within a ternary complex. FEBS Lett. 228:1988;273-276.
80. Praseuth D., et al. Sequence-specific binding and photocrosslinking of alpha and beta oligodeoxynucleotides to the major groove of DNA via triple-helix formation. Proc. Natl. Acad. Sci. USA. 85:1988;1349-1353.
81. Praseuth D., et al. Sequence-targeted photosensitized reactions in nucleic acids by oligo-alpha-deoxynucleotides and oligo-beta-deoxynucleotides covalently linked to proflavin. Biochemistry. 27:(8):1988;3031-3038.
82. Le Doan T., Perrouault L., Chassignol M. Sequence-targeted chemical modifications of nucleic acids by complementary oligonucleotides covalently linked to porphyrins. Nucleic Acids Res. 15:1987;8643.
83. Le Doan T., Perrouault L., Chassignol M. Sequence-specific chemical and photochemical reactions on nucleic acids by oligonucleotides linked to porphyrins (abstract). J. Inorg. Biochem. 36:1989;274.
84. Le Doan T., et al. Sequence-targeted photochemical modifications of nucleic acids by complementary oligonucleotides covalently linked to porphyrins. Bioconjug. Chem. 1:(2):1990;108-113.
85. Lee B.L., et al. Interaction of psoralen-derivatized oligodeoxyribonucleoside methylphosphonates with single-stranded DNA. Biochemistry. 27:(9):1988;3197-3203.
86. Lee B., et al. Identification of the molecular defect in a family with spondyloepiphyseal dysplasia. Science. 244:1989;978-980.
87. Praseuth D., et al. Double helices with parallel strands are formed by nuclease-resistant oligo-(alpha)-deoxynucleotides and oligo-(alpha)-deoxynucleotides covalently linked to an intercalating agent with complementary oligo-(beta)-deoxynucleotides. J. Mol. Biol. 196:(4):1987;939-942.
88. Perrouault L., et al. Sequence-specific artificial photo-induced endonucleases based on triple helix-forming oligonucleotides. Nature. 344:1990;358-360.
89. Helene C., Thuong N.T. Control of gene expression by oligonucleotides covalently linked to intercalating agents. Genome. 31:(1):1989;413-421.
90. Kean J.M., et al. Photochemical cross-linking of psoralen-derivatized oligonucleoside methylphosphonates to rabbit globin messenger RNA. Biochemistry. 27:(26):1988;9113-9121.
91. Saison-Behmoaras T., et al. Short modified antisense oligonucleotides directed against Ha-Ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation. EMBO J. 10:1991;1111-1118.
92. Moser H.E., Dervan P.B. Sequence-specific cleavage of double helical DNA by triple helix formation. Science. 238:1987;645-650.
93. P. Dervan, Oligonucleotide recognition of double-helical DNA by triple-helix formation, in: J. Cohen (Ed.), Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL, 1989, p. 197.
94. Chu B.C., Orgel L.E. Nonenzymatic sequence-specific cleavage of single-stranded DNA. Proc. Natl. Acad. Sci. USA. 82:(4):1985;963-967.
95. Boutorin A., Vlassov V., Kazakov S. Complementary addressed reagents carrying EDTA-Fe(II) groups for directed cleavage of single-stranded nucleic acids. FEBS Lett. 172:1984;43.
96. Francois J.C., et al. Periodic cleavage of poly(dA) by oligothymidylates covalently linked to the 1,10-phenanthroline-copper complex. Biochemistry. 27:(7):1988;2272-2276.
97. Francois J.C., et al. Sequence-specific recognition and cleavage of duplex DNA via triple-helix formation by oligonucleotides covalently linked to a phenanthroline-copper chelate. Proc. Natl. Acad. Sci. USA. 86:(24):1989;9702-9706.
98. Francois J.C., et al. Sequence-targeted cleavage of single- and double-stranded DNA by oligothymidylates covalently linked to 1,10-phenanthroline. J. Biol. Chem. 264:1989;5891-5898.
99. Sun J.-S., et al. Sequence-targeted cleavage of nucleic acids by oligo-α-thymidylate phenanthroline conjugates: parallel and antiparallel double helices are formed with DNA and RNA, respectively. Biochemistry. 27:1988;6039-6045.
100. Chen C.H., Sigman D.S. Nuclease activity of 1,10-phenanthroline-copper: sequence-specific targeting. Proc. Natl. Acad. Sci. USA. 83:(19):1986;7147-7151.
101. C. Helene, T. Le Doan, N. Thuong, Sequence-targeted photochemical reactions in single-stranded and double-stranded nucleic acids by oligonucleotide-photosensitizer conjugated, in: P. Nielson (Ed.), Photochemical Probes in Biochemistry, Kluwer Academic, Dordrecht, 1989, p. 219.
102. C. Helene, N. Thuong, Oligodeoxynucleotides covalently linked to intercalating agents and to nucleic acid-cleaving reagents. New families of gene regulatory substances, in: Working Group on Molecular Mechanisms of Carcinogenic and Antitumor Activity, Pontificaiae Academiae Scientarium Scripta Varia, Vatican City, 1987.
103. Cech T.R. The chemistry of self-splicing RNA and RNA enzymes. Science. 236:1987;1532-1539.
104. McSwiggen J.A., Cech T.R. Stereochemistry of RNA cleavage by the Tetrahymena ribozyme and evidence that the chemical step is not rate-limiting. Science. 244:1989;679-683.
105. Uhlenbeck, O., Using ribozymes to cleave RNAs, in: S. Crooke B. Lebleu (Eds.), Antisense Research and Applications, CRC Press, Boca Raton, FL, 1993, p. 83.
106. Haseloff J., Gerlach W.L. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature. 334:1988;585-591.
107. McCall M.J., Hendry P., Jennings P.A. Minimal sequence requirements for ribozyme activity. Proc. Natl. Acad. Sci. USA. 89:(13):1992;5710-5714.
108. Chowrira B.M., et al. Four ribose 2′-hydroxyl groups essential for catalytic function of the hairpin ribozyme. J. Biol. Chem. 268:(26):1993;19458-19462.
109. Koizumi M., Ohtsuka E. Effects of phosphorothioate and 2-amino groups in hammerhead ribozymes on cleavage rates and Mg2+ binding (published erratum appears in Biochemistry 31(16) (1992) 4156). Biochemistry. 30:(21):1991;5145-5150.
110. Heidenreich O., et al. High activity and stability of hammerhead ribozymes containing 2′-modified pyrimidine nucleosides and phosphorothioates. J. Biol. Chem. 269:1994;2131-2138.
111. Pieken W.A., et al. Kinetic characterization of ribonuclease-resistant 2′-modified hammerhead ribozymes. Science. 253:1991;314-317.
112. Olsen D.B., et al. Study of a hammerhead ribozyme containing 2′-modified adenosine residues. Biochemistry. 30:1991;9735-9741.
113. Goodchild J. Enhancement of ribozyme catalytic activity by a contiguous oligodeoxynucleotide (facilitator) and by 2′-O-methylation. Nucleic Acids Res. 20:1992;4607-4612.
114. Forster A.C., Altman S. External guide sequences for an RNA enzyme. Science. 249:(4970):1990;783-786.
115. Yuan Y., Hwang E.S., Altman S. Targeted cleavage of mRNA by human RNase P. Proc. Natl. Acad. Sci. USA. 89:(17):1992;8006-8010.
116. Herschlag D., Cech T.R. DNA cleavage catalysed by the ribozyme from Tetrahymena. Nature. 344:1990;405-409.